Back to Search
Start Over
Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2022 Aug 15; Vol. 61 (16), pp. 2497-2502. Date of Electronic Publication: 2022 Feb 01. - Publication Year :
- 2022
-
Abstract
- A 49-year-old woman presented with nephrotic-range proteinuria, microhematuria, and moderate renal dysfunction. Diuretic-resistant refractory ascites associated with nephrotic syndrome were observed. Based on the histopathological findings, the patient was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID). Rituximab was administered due to steroid and immunosuppressive drug resistance, and partial remission was achieved after six months. Cell-free and concentrated ascites reinfusion therapy (CART) performed to treat the refractory ascites improved the ascites and anasarca. Rituximab successfully treated the PGNMID, while CART effectively treated the refractory ascites associated with nephrotic syndrome.
- Subjects :
- Antibodies, Monoclonal therapeutic use
Ascites complications
Ascites drug therapy
Female
Humans
Immunoglobulin G therapeutic use
Middle Aged
Rituximab therapeutic use
Glomerulonephritis complications
Glomerulonephritis drug therapy
Glomerulonephritis, Membranoproliferative drug therapy
Nephrotic Syndrome complications
Nephrotic Syndrome drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 61
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 35110486
- Full Text :
- https://doi.org/10.2169/internalmedicine.8799-21